- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
McKesson to Pay $151 Million to Settle Drug-Pricing Suit
McKesson Corp. will pay $151 million to 29 states over allegations the company artificially raised Medicaid drug prices for years, the latest settlement over claims the pharmacy supply chain overcharged for prescription medications.
McKesson, the nation's largest drug wholesaler by revenue, deliberately drove up the prices of some 1,400 brand-name drugs from 2001 to 2009, state and federal officials alleged in a lawsuit. Prices for some widely used blockbuster drugs, like Pfizer Inc.'s Lipitor or Eli Lilly & Co.'s Prozac, rose by as much as 25%, causing Medicaid programs to overpay by millions, state officials said.
Read the full story: http://tinyurl.com/bpjvts2
Source: The Wall Street Journal
Impact of Medicaid Institution for Mental Diseases Exclusion on Serious Mental Illness Outcomes
December 17th 2025Medicaid’s Institution for Mental Diseases (IMD) rule bars federal funding for psychiatric facilities with more than 16 beds, but findings indicate that state waivers allowing treatment of serious mental illness in IMDs do not increase overall psychiatric hospitalizations.
Read More
